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1. SUMMARY 
In the recent years, the effectiveness of some antibiotics is progressively decreasing due to 
the emerge of multidrug resistance bacteria while the development of new antibiotics is slow and 
complex procedure. Thus, it is one of the biggest public health problems because they can cause 
some disease which are difficult, and sometimes impossible, to treat. In general, this resistance 
is caused by irreversible mutations in bacterial genes and can be prevented by minimising the 
misuse of antibiotics. 
KR-12 is the smallest antimicrobial peptide of human cationic LL-37 peptide. Thus, shorter 
peptide possessed the same antimicrobial and anti-inflammatory activities than the biggest one 
but without the associated mammalian cell toxicity. The production cost of KR-12 is much lower 
than LL-37 and it is also faster to obtain. It plays an essential role in protecting humans against 
infectious diseases and it has wound healing, immune modulating and anticancer effects. 
The aim of this work is to synthesize this peptide by solid phase peptide synthesis using 
Fmoc/tBu protection strategy. Secondly, it has been designed and synthetized a KR-12 analog in 
order to improve its activity by accoupling a fatty acid group. Finally, these peptides have been 
characterized by using RP-HPLC and ESI mass spectroscopy. They have been obtained in 
moderated yield and high purity. 
Furthermore, the microbiological activity of both peptides has been evaluated by determining 
their minimum inhibitory concentration (MIC) and, also, has been studied their toxicity by 
hemolytic assay. 
Keywords: antibiotic peptides, KR-12 peptide, solid phase, microbiological activity, hemolysis. 
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2. RESUM 
En els últims anys, l’efectivitat d’alguns antibiòtics està disminuint progressivament a causa 
de l’aparició de bacteris multi-resistents, mentre que, el desenvolupament de nous antibiòtics és 
un procés lent i complex. Això fa que sigui un dels majors problemes de l’actual salut pública, ja 
que, poden causar malalties difícil de ser tractades o inclús impossible. En general, aquesta 
resistència és causada per mutacions irreversibles en els gens bacterians i es pot prevenir 
minimitzant el mal ús dels antibiòtics. 
El KR-12 és el pèptid antimicrobià més petit del pèptid humà catiònic LL-37. El més curt 
posseeix les mateixes activitats antimicrobianes i antiinflamatòries que el més llarg però sense la 
toxicitat associada a les cèl·lules dels mamífers. El cost de producció de KR-12 és molt inferior 
al del LL-37 i també és més ràpid d’obtenir. Aquest pèptid té un paper essencial en la protecció 
dels humans contra les malalties infeccioses i a part, té poder de cicatrització de ferides, efectes 
immuno-moduladors i contra el càncer. 
L’objectiu d’aquest treball és sintetitzar aquest pèptid mitjançant síntesi de pèptids en fase 
sòlida utilitzant l’estratègia de protecció de Fmoc/tBu. En segon lloc, s'ha dissenyat i sintetitzat 
un anàleg del KR-12 per millorar la seva activitat acoblant un àcid gras. Finalment, aquests 
pèptids s’han caracteritzat mitjançant l’ús de RP-HPLC i ESI-MS. S'han obtingut amb rendiment 
moderat i un elevada puresa. 
A més, l’activitat microbiològica d’ambdós pèptids s’ha avaluat determinant la seva 
concentració mínima inhibidora (MIC) i, també, s’ha estudiat la seva toxicitat mitjançant 
l’hemòlisis. 
Paraules clau: pèptids antibiòtics, pèptid KR-12, fase sòlida, activitat microbiològica, hemòlisi. 
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3. INTRODUCTION 
Antibiotics are chemical substances used as powerful medicines that fight bacterial infections, 
not caused by virus. They have the capacity in dilute solutions to inhibit the growth of bacteria or 
to destroy it. 
If they are used properly, antibiotics can save lives. But with the advent of the antibiotic era, 
the overuse and inappropriate consumption have driven the rapid emergence of multidrug 
resistance pathogens. Antimicrobial resistance increases the morbidity, mortality length of 
hospitalization and healthcare costs. Antibiotic resistance is considered a major threat for human 
health. [1] 
The growing drug resistance problem of pathogenic bacteria with traditional antibiotics calls 
for an urgent search for a new generation of antimicrobial agents. Antimicrobial peptides are 
ancient and potent weapons of the innate immunity of all life forms. The recently updated 
Antimicrobial Peptide Data base collects 3072 antimicrobial peptides. [2,3] 
3.1. ANTIMICROBIAL PEPTIDES (AMPS) 
Antimicrobial peptides are small molecular weight proteins with 10-50 amino acids in general. 
They are a new class of antibiotics. Unlike traditional antibiotics, they have broad-spectrum 
antimicrobial ability with lower cytotoxicity and accordingly, they have the potential to replace the 
use of traditional antibiotics against bacteria, viruses and fungi. So, they are an alternative to 
classical AMPs due to their non-cytotoxic activity and high efficacy. [4] 
AMPs are characterized by an amphiphilic configuration, derived from the presence of cationic 
residues on one side of the peptide and hydrophobic residues on the opposite side. The 
amphipathic nature of AMPs allows them to interact with negatively charged bacterial membranes 
and perturb the membrane bilayer.  
Human express a variety of AMPs, grouped into three major classes: cathelicidin, defensins, 
and histatins, which differ in structure and residue composition. [5] 
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3.2. SOLID PHASE PEPTIDE SYNTHESIS 
Bruce Merrifield described a revolutionary method in 1969, the solid phase peptide synthesis 
(SPPS). This method allowed a much shorter and faster way to produce peptides with much 
higher yield than the classical synthesis. Nowadays, there are optimized techniques that allow to 
synthesize a peptide with 100 amino acids in just four days with reasonable yields. [6] 
The concept of SPPS is based on attaching the first amino acid, the C-terminal residue, to a 
resin. To prevent the polymerization of the amino acid, the alpha amino group and the reactive 
side chains are protected with a temporary protecting group. The protective group is then removed 
and each protected amino acid N-terminal is added, one by one, with other necessary reagents, 
so that the peptide is synthesized from C-terminal to the N-terminal end. The cycle is repeated 
until the peptide sequence is complete. The peptide is washed after each step of the procedure, 
in order to remove by-products and excess reagents with vacuum filtration. 
Ideally, the N alpha protecting group and the side chain protecting groups should be 
removable under completely different conditions, such as basic conditions to remove the N alpha 
protection and acidic conditions to remove the side chain protection. This selective protection is 
called “orthogonal” protection. 
Finally, all the protecting groups are removed, and the peptide is cleaved from the resin by 
an acid treatment. [6,7] 
 
 
 
 
 
 
 
 
 
 
    Figure 1. SPPS cycle (AA= amino acid, P1= basic labil protecting group, P1= acid labil protecting group). 
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3.3. KR-12 
LL-37 is the only human cationic peptide. It plays an essential role in protecting humans 
against infectious diseases and it is produced by epithelial cells. This peptide is composed of 37 
amino acids starting with a pair of leucines. It is known to have broad-spectrum of antibacterial 
activity against bacteria, viruses, fungi and parasites and can enter the cell to play a role in 
immune regulation. This peptide plays a decisive part in eliminating bacteria under physiological 
conditions. It is thought that LL-37 kills bacteria directly through regulating the body’s defence 
system. When bacterial infection occurs, LL-37 is produced by epithelial cells and released from 
the neutrophil granules. Thus, patients who don’t have this molecule are more susceptible to 
infections. In addition, it has wound healing, immune modulating and anticancer effects. [4,8] 
Human LL-37 is relatively long and can be costly to synthesize chemically. Thus, it is usually 
to cut LL-37 by removing unwanted regions. KR-12 is the shortest antibacterial peptide of human 
LL-37, corresponding to residues 18-29. The amino acid sequence is KRIVQRIKDFLR. This 
sequence included five positively charged amine groups (3 Rs and 2 Ks), that could recruit 
negatively charged bacteria to the KR-12. [1,9] 
Use of KR-12 peptide eliminates the toxicity problems associated with LL-37. Thus, shorter 
peptide possessed the same antimicrobial and anti-inflammatory activities than the biggest one 
but without the associated mammalian cell toxicity.  
The use of AMP antimicrobial coatings in the Ti implants has been widely investigated, due 
to their lower cytotoxicity and minimal development of pathogen resistance compared to 
conventional antibiotics. Infection and poor bone-implant integration are two main reasons for 
titanium (Ti) implant failure. The KR-12 peptide can be covalently immobilized on the Ti surface 
by the covalent bond between the amine groups on the Ti surface and the carboxyl groups of the 
peptide. [10] 
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4. OBJECTIVES 
The main objectives in this work are the following: 
• Synthesis of KR-12 using solid phase peptide synthesis. 
• Design and synthesis of KR-12 analog in order to improve its activity. 
• Purify the obtained peptides by semi-preparative HPLC and characterize them by 
analytical HPLC and ESI mass spectrometry. 
• Evaluate the antimicrobial activity of the synthesized peptides by using MIC test. 
• Evaluate the toxicity of the synthesized peptides by hemolysis assay. 
5. EXPERIMENTAL SECTION 
5.1. MATERIALS 
5.1.1. Solvents and reagents 
5.1.1.1. Solvents 
Solvent Quality Brand 
Acetone Synthesis Scharlau 
ACN HPLC Carlo Ebra 
DCM(a) Synthesis VWR 
DMF Synthesis Carlo Erba 
Et2O(b) Synthesis Scharlau 
H2O(c) Milli-Q - 
Isopropanol HPLC Fisher Scientific 
MeOH HPLC Fisher Scientific 
(a) DCM is filtered through a basic alumina column. 
(b) The dried Et2O is kept over sodium. 
(c) The deionized water is filtered with a MiIli-Q (Millipore) system. 
Table 1. Solvents and their specifications. 
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5.1.1.2. Reagents 
Reagents Quality Brand 
Resin, RL and 
amino acids 
- Bachem 
Iris Biotech 
NeMPS 
Fisher Scientific 
DIC Pure, 99% Sigma-Aldrich 
DIEA Reagent Plus®, 99% Sigma-Aldrich 
HOBt Pure, 99% Fluka 
MHB - Oxoid 
Na2CO3 - Jescuder 
Ninhydrin Pure Iris Biotech 
Octanoic acid Pure, ≥ 98% Sigma-Aldrich 
Piperidine Reagent Plus®, 99% Sigma-Aldrich 
TFA Synthesis Fluorochem 
TIS Pure, 99% Acros organics 
TRIS - Sigma-Aldrich 
Table 2. Reagents for peptide synthesis and products for biological assays and their specifications. 
 
5.1.2. Instrumentation 
Instrument Brand and model 
Autoclave AUTESTER-E 
Centrifuge -Hettich ROTOFIX 32 A 
-Sigma 201M  
HPLC -Analytitcal: Shimadzu Serie 20 
Prominence, with two pumps LC-20AD, 
automatic SIL-20A injector, controller 
CBM-20A and detector SPD-M20A 
-Semipreparative: Waters Delta Prep 
3000, with a Waters 600E pump and a 
manual sample injector Eaters 712, 
Water 484 detector and a data recorder 
Pharmacia Biotech RED 101  
Lyophilizer Christ Alpha 2-4 LDplus 
Mass spectrometer Zq-Micromass (Waters) 
Microplate reader BioTek Synergy HT  
Spectrophometer Shimadzu UV-1700 PharmaSpec 
Table 3. Instrumentation and their specifications. 
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5.2. METHODS 
5.2.1. Ninhydrin test 
Ninhydrin test or Kaiser test is a very sensitive assay used in SPPS to determine if the amino 
acid coupling has been done at all. The reaction of ninhydrin with primary amino groups of the N-
terminal side form a dark blue or intensive purple colour. This means that the coupling reaction is 
not complete thus it’s necessary to recouple. For a better yield, ninhydrin test should be performed 
after each coupling. [11] 
To perform the test, three solutions are required: 
Reagent A: ninhydrin (2,5g) are dissolved in EtOH (50mL). The solution prepared must be 
kept protected from light. 
Reagent B: phenol (50mg) is diluted in EtOH (100mL). Then the solution is filtered. 
Reagent C: KCN (65mg) is added in H2O (100mL), 2mL of the resultant solution are added in 
100mL of distilled pyridine. Then the solution is filtered. 
To carry out the assay, a little sample of peptide-resin (washed with DMF, then with DCM and 
finally dried with a vacuum pump) is introduced in a small test tube. Two drops of each reagent 
(named above as A, B and C) are added and the mixture is heated in a sand bath at 110ºC for 
3´.  
After that, if the solution turns blue/purple (positive assay) free amino groups are present and 
a recoupling step is necessary. In contrast, if the solution remains yellow (negative assay) means 
that the coupling is successful at least 99,5% because no free primary amines are present. 
As shows Figure 2, ninhydrin (1, which is a yellow compound) reacts with a primary amine of 
amino acid (2) forming and imine (3), in a nucleophilic addition-elimination reaction. Then, there 
is a decarboxylation reaction, and after that the imine (5) reacts with H2O in a hydrolysis reaction 
to form an aldehyde and a free amine again (6). Compound 6 reacts with another equivalent of 
ninhydrin forming 7 and finally 8, which is the purple compound. [6]   
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Figure 2. Reaction mechanism of ninhydrin assay. 
5.2.2. Purification  
High performance liquid chromatography is an analytical technique used to separate, 
identify and quantify each component in a mixture. It is based in the different molecular weight 
and polarity of the analytes. It has a column through which pass pressurized liquid solvent with 
the sample mixture at high pressure (it achieves 400 atmospheres) that makes it much faster. 
Each component in the sample interacts differently with the adsorbent of the column, 
causing diverse retention times and leading to the separation of the components as they flow 
out of the column. The elution of bound components occurs by increasing the concentration of 
organic solution (ACN). This technique has a non-polar stationary phase and an aqueous 
mobile phase which is moderately polar. So, retention time is longer for molecules which are 
less polar while polar molecules elute faster. 
5.2.2.1. Semi-preparative RP-HPLC 
The peptides are purified by semi-preparative RP-HPLC. As they have different retention 
time produced by the different hydrophobicity of the molecule, this technique is used to purify 
compounds from a mixture. Finally, you will get the single compound at a certain purity level. 
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The column used is Phenomenex C18 of reverse phase (1 x 25 cm, 5 μm diameter particle). 
The samples are eluted at 2mL/min flow rate with a lineal gradient of 0,1% TFA/H2O (A) and 
0,1% TFA/ACN (B) and UV detection at 220 nm. 
5.2.3. Characterization 
Two different techniques have been used to carry out the characterization of the peptides. 
5.2.3.1. Analytical RP-HPLC 
The objective of analytical RP-HPLC is to identify and quantify the components of the mixture. 
The difference with the previous RP-HPLC is the amount of sample applied. In semi-preparative 
the quantity is higher than in analytical. 
The column used is a Phenomenex C18 of reverse phase (0,46 x 25 cm) packed with 
octadecylsiloxane of 5 μm diameter particle. The samples are eluted at a flow rate of 1mL/min 
using the lineal gradients of 0,045% TFA/H2O (A) and 0,036% TFA/ACN (B) and UV detection at 
220 nm. 
5.2.3.2. ESI mass spectroscopy 
Mass spectroscopy is an analytical technique that separate the components of a sample by 
their mass and electrical charge. It produces a mass spectrum that plots the intensity of the mass-
to-charge (m/z) ratio of ions in a mixture. 
The electrospray ionization (ESI) is a soft ionization technique. It is a desorption ionization 
method and it is produced by applying a strong electric field to a liquid passing through a capillary 
tube. The transfer of ions from solution into the gaseous phase can thus be analysed by 
spectrometric analysis with increased sensibility. The different charged ions travel through the 
mass analyser and arrive at different parts of the detector according to their m/z ratio. The 
spectrum shows the m/z ratio on the x-axis and the abundance (%) on the y-axis. 
The samples analyzed are peptide solutions in H2O/ACN (1:1, v/v). A positive mass spectrum 
is obtained using the spectrometer ZQ-Micromass (Waters). The signals are caused by ionization 
with proton or another cation such as Na+ or K+. Moreover, multiply charged ions are also 
observed. 
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5.3. SOLID PHASE PEPTIDE SYNTHESIS 
5.3.1. Synthesis (Fmoc/tBu strategy)  
The peptide is synthesized manually by SPPS following the Fmoc/tBu strategy. It is carried 
out using polypropylene syringes from Terumo with a porous polyethylene filter from Teknokroma. 
After each coupling, by-products and reagents can be removed by vacuum filtration. The reagent 
mixture is stirred with a Teflon wand. 
The concept of SPPS is based on attaching the first AA to a resin, then proceeding with 
peptide chain elongation. A resin is composed of a polymeric solid support linked permanently to 
a linker that facilitates temporary anchoring of the first AA to the polymeric solid support. 
5.3.1.1. Loading the resin 
The BHA commercial resin used (f=0,69) needs a pre-treatment because it is stored in a 
compact form. Thus, impurities will be eliminated. The protocol used is described in Table 4. 
Step Reagent Function Time Repetitions 
1 DCM Wash 30’’ 5 
2 TFA/DCM 40% Wash and solvate 1’ 1 
3 TFA/DCM 40% Wash and solvate 10’ 2 
4 DCM Wash 30’’ 5 
5 DIEA/CH2Cl2 5% Neutralization 2’ 3 
6 DCM Wash 30’’ 5 
7 DMF Wash 30’’ 5 
 
Table 4. Protocol used to load BHA resin. 
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5.3.1.2. Reference amino acid coupling 
L-Fmoc-(L)-Val-OH used as reference amino acid in the synthesis of the two peptides is 
added to the BHA resin with DIC and HOBt with the minimum quantity of DMF for 1 hour. The 
coupling is confirmed by ninhydrin test and the coupling protocol used is shown in Table 6. 
5.3.1.3. Rink Linker incorporation 
To coupling the Rink Linker is necessary to remove Fmoc from amino acid reference in 
order to deprotect it, as shown in Table 5.  
Step Reagent Function Time  Repetitions 
1 DMF Wash 30’’ 5 
2 20% piperidine/DMF Deprotection 1’ 1 
3 20% piperidine/DMF Deprotection 10’ 2 
4 DMF Wash 30’’ 5 
Table 5. Fmoc deprotection protocol. 
After this, the Rink Linker incorporation is carried out by following the protocol shown in Table 
6 and by replacing step 2 for the addition of 1,8 eq. of RL, HOBt and DIC overnight to the BHA 
with a minimum quantity of DMF. After overnight reaction the coupling is confirmed by ninhydrin 
test. 
5.3.1.4. Elongation of the peptide  
To perform the peptide chain elongation, it is necessary to have the terminal amino group 
deprotected. After this step, the first amino acid can be coupled using an excess of amino acid, 
HOBt and DIC (3 eq.) with the minimum quantity of DMF for 1 hour as shown in Table 6. The 
protocol includes three general groups: the amino acid coupling, the ninhydrin test and the 
removal of Fmoc group. When the synthesis is finished, the peptide-resin is washed with DMF 
and DCM and dried in vacuum. 
Synthesis and study of antibiotic peptides  17 
 
(a) The reagents are added to the resin with a minimum quantity of DMF 
(b) If the ninhydrin test became positive, 1.5 eq of each reagent in DMF are added in the mixture for 30 extra minutes 
Table 6. Elongation peptide chain protocol by Fmoc/tBu strategy.   
At the end of the peptide sequence, the resin is divided in two equal parts: one of them will 
be finished (KR-12 peptide) and the other one will be coupled two glycines and a fatty acid group 
(KR-12 peptide analog). 
5.3.1.5. Fatty acid coupling 
After coupling the two Glycines to KR-12 peptide, the next step is to incorporate the fatty acid 
group following the procedure described in Table 7.  
Step Reagent Function Time Repetitions 
1 DMF Solvate 30’’ 5 
2 5 eq. Fatty acid (octanoic acid) 
5 eq. HOBt 
5 eq. DIC 
Coupling 60’ 1 
3 DMF Wash 30’’ 5 
4 DCM Wash 30’’ 5 
5 Ninhydrin test Coupling control 3’ 1 
6 DMF Solvate 30’’ 5 
7 DCM Wash 30’’ 5 
Table 7. Fatty acid coupling protocol. 
Step Reagent Function Time  Repetitions 
1 DMF Solvate 30’’ 5 
2 3 eq. Fmoc-AA-OH a 
3 eq. HOBt 
3 eq. DIC 
Coupling 60’ 1 
3 DMF Wash 30’’ 5 
4 DCM Wash 30’’ 5 
5 Ninhydrin test b Coupling control 3’ 1 
6 DMF Solvate 30’’ 5 
7 20% piperidine/DMF Deprotection 1’ 1 
8 20% piperidine/DMF Deprotection 10’ 2 
9 DMF Solvate 30’’ 5 
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5.3.2. Cleavage 
The aim of this step is to separate the peptide from the solid support and from the side-chain 
protecting groups. To achieve it, it requires a strong acid such as TFA. The procedure is carried 
out by acidolysis with 5 mL TFA/TIS/H2O (95:3:2, v/v). This mixture is added to the resin in the 
syringe and it is left to react for 90 min. Triisopropylsilane (reductant) and water (nucleophile) act 
as cation scavengers.  
TFA is removed by evaporation with N2 stream and the crude product obtained is treated with 
Et2O (20 mL) to precipitate the peptide. The solid peptide is isolated by centrifugation at 6000 
r.p.m. for 10 min and the supernatant is poured off. The peptide is dissolved in H2O/ACN, 
lyophilized and analysed by analytical HPLC and by ESI mass spectroscopy.  
In addition, to check the evolution of the sequence, it is possible to carry out cleavage tests 
during the chain elongation with a little sample of the resin in 1mL of the cleavage solution. [11] 
5.3.3. Purification and characterization 
The peptides are purified by semi-preparative HPLC. Then they are lyophilized with high 
purities (≤99%) as determined by analytical RP-HPLC and followed by UV detection at 220 nm, 
as amine bonds absorb light at this wavelength. The peptides are obtained in TFA salt form and 
the yields achieved are shown in Table 8.  The yields are moderately good, because the synthesis 
have a lot of steps. Moreover, various ninhydrin tests and mini-cleavages are carried out which 
causes product losses. 
The purified peptides are characterized by analytical RP-HPLC and ESI mass spectroscopy. 
Chromatograms are shown in Appendix 2 and ESI spectrums are in Appendix 3. 
Peptide Synthesis yield [%] Purity [%] RP-HPLC (tR) 
[min] (a) 
HRMS ESI+ 
KR-12 10,8 99,0 20,310 m/z 1571,81 (<1%, [M+H]+), 
786,23 (49%, [(M+2H)/2]2+), 
524,45 (100%, [(M+3H)/3]3+), 
389,34 (30%, [(M+4H)/4]4+) 
Analog 12,3 99,7 13,349 m/z 906,7 (39%, [(M+2H)/2]2+), 
604,8 (100%, [(M+3H)/3]3+), 
453,8 (53%, [(M+4H)/4]4+) 
(a) RP-HPLC: lineal gradient from 10% to 25% of B for 30 min, at flow 1 mL/min in KR-12 and 30% of B to 45% in analog.       
Table 8.  Purification yields and final characterization of synthesized peptides. 
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5.4 EVALUATION OF ANTIMICROBIAL ACTIVITY 
One of the main objectives of this work is to characterize antibacterial activity of peptides. It 
has been used four bacterial strains, one of them is Gram-positive (Staphylococcus aureus) and 
the other ones are Gram-negative (Escherichia coli, Pseudomonas aeruginosa, Acinetobacter 
baumannii).  
5.4.1. Preparation of material and medium 
First of all, the material and growth medium of bacteria must be autoclaved in order to 
eliminate any form of life. The medium used is Muller Hinton-Broth (MHB) and two different culture 
mediums need to be prepared: 1 x concentrated MHB (21 g in 1 L of Milli-Q Water) and 2 x 
concentrated MHB (42 g in 1 L of Milli-Q Water). 
So, pipette tips, bowl for Multi-Channel Pipette, glass bottles, flask and the medium need to 
be autoclaved before its use. 
5.4.2. Growth and inoculation of bacteria  
The microorganisms used are: 
• Gram-negative bacteria: Escherichia coli ATCC 25922, Pseudomonas aeruginosa 
ATCC 27853, Acinetobacter baumannii ATCC 19609. 
• Gram-positive bacteria: Staphylococcus aureus ATCC 25293. 
The day before the MIC test, in a test tubes are prepared one colony of each bacterium with 
1xMHB solution and leave at 37ºC overnight.  
The next day, the absorbance is measured and adjusted to 0,3-0,35 at 550nm. Then, after 4 
hours at 37ºC is measured again and is adjusted to the same value. At that point, it is diluted 
1:100 or 1:10 (depends on the bacteria) in a cultive bath and these solutions are ready to start 
the MICs.  
5.4.3. Preparation of peptide solutions  
For each peptide a solution of 512 µg/mL is prepared with Milli-Q water. This table shows the 
quantity of each one. 
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Peptide Weight [mg] Real weight [mg] (a) Volume of Milli-Q Water 
[µL] 
KR-12 0,86 0,63 1232 
Analog 0,98 0,78 1529 
(a) Peptides are positively charged so they contain the counterion CF3COO- from TFA. Thus, the real weight corresponds to the 
peptide without the counterion. 
Table 9. Peptides solution for the MIC test 
5.4.4. Determination of MIC  
The determination is carried out in 96-well plate (8 rows: from A to H; 12 columns: from 1 to 
12), one for each bacterium. In order to add the different volumes of solutions is used a 
multichannel pipette. The procedure followed is: 
1) 50 µL of 2xMHB are added to column 1, 50 µL of 1xMHB to column 2 to 11 and 100 µL of 
1xMHB to column 12. 
2) 50 µL of peptide solution are added to column 1. With the help of the multichannel pipette, 
the mixture in column 1 is stirred and 50 µL of this column is added to column 2. This step is 
repeated until column 10 where 50 µL are picked up and thrown away. The concentration of 
peptide in each column decreases by a half to 128 µg/mL (column 1) to 0,25 µg/mL (column 10). 
3) 50 µL of bacterial solution are added to column 1 to 11. So, the final concentration of 
bacteria in each well will be 105-106 CFU/mL. It is a standard value in order to be able to compare 
the results with others. 
4)The last step is to incubate the plates at 37ºC for 20-22h.  
Thus, column 11 is the positive control (it contains bacteria and MHB, so bacteria will grow 
without the peptide) and column 12 is the negative control (it just contains MHB). 
The following day, it is evaluated the growth of bacteria by their turbidity with each peptide. 
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Figure 3. Preparation of the microtiter plates for the MIC test. 
5.5. EVALUATION OF TOXICITY 
The next assay is to determine the toxicity of the KR-12 peptide and its analog and compare 
them. 
5.5.1. Hemolytic assay 
The hemolytic activity is investigated using rabbit’s blood. The procedure followed was: 
1. First of all, blood needs to be washed with TBS (TRIS 10mM and NaCl 150mM). The 
mixture is centrifuged (10’, 4000 r.p.m., 4ºC), removing the supernatant (TBS) in order to separate 
the precipitate (red blood cells). Isolated red blood cells are washed thrice with buffer/TBS. 
2. When concentrated red cells are obtained, they are adjusted to a certain value of 
absorbance at 540nm by adding drop of blood to a X quantity of TBS. 
E. coli 
P. aeruginosa 
S. aureus 
A. baumannii 
Column 1: 50 µL 2xMHB 
+ 50 µL peptide 
Column 2-11: 50 µL 1xMHB  
Column 11: positive control 
Column 12: negative control  
50 µL 50 µL 50 µL 
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3. For each peptide, 1mL of a solution of 1024µg/mL is prepared dissolving the 
correspondent amount of the peptide in TBS buffer. Next step is to prepare 10 Eppendorf with the 
same quantity of blood but with different concentration of peptide. The first Eppendorf are mixed 
200 µL of TBS with 200 µL of peptide solution. The mixture in this Eppendorf is stirred and 200 
µL of it is added to Eppendorf 2 which also contains 200 µL of TBS. This step is repeated until 
Eppendorf 10 where 200 µL are picked up and thrown away. Then, 200 µL of blood is added. 
The concentration of peptide in each one decreases by a half to 256 µg/mL (Eppendorf 1) to 0,5 
µg/mL (Eppendorf 10). Then, it is needed to confirm that the absorbance is 1. 
4. In addition, a 0% and 100% hemolysis controls are needed. Both are prepared with the 
same quantity of blood as before but the medium in 0% is TBS while in 100% of hemolysis it must 
be water or Triton X-100 (surfactant). 
5.  All these solutions are incubated at 37ºC for 1h. 
6. After that, they are centrifugated (5’, 4000 r.p.m., 4ºC) 
7. It is added 200µL from the supernatant of each Eppendorf to each well of a microtiter 
plate. 
8. The absorbance of the mixture is read at 540nm. 
 
 
6. KR-12 ANALOGS  
The main objective in this work is to obtain KR-12 peptide using solid phase peptide synthesis. 
In order to improve its activity a new antimicrobial peptide derived from this one is synthesized. 
Many studies demonstrated that the attachment of aliphatic fatty acid to N-terminus of 
positively charged peptides can compensate the hydrophobicity of the peptide chain. This 
generate new artificial lipopeptides more hydrophobic with potent antibacterial activities. Thus, 
the peptide chain causes more hydrophobic interactions with bacteria and may facilitate the 
penetration of the antimicrobial peptide. Also, this incorporation can destabilize the membrane. 
[12,13] 
6.1. DESIGN 
The principal changes between both peptides are that analog has a fatty acid group coupled: 
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• In order to obtain the analog, first of all it is necessary to have KR-12 peptide 
synthesized at all. After, two glycines are coupled as spacer. Finally, the fatty acid 
group (octanoic acid) is added. Theoretically, this change will affect the 
hydrophobicity of the molecule. 
The sequence of the synthesized peptides is shown in Table 10 and the structure is shown 
in Figure 4. 
Peptide Sequence 
KR-12 Lys-Arg-Ile-Val-Gln-Arg-Ile-Lys-Asp-Phe-Leu-Arg-NH2 
Analog C8-Gly-Gly-Lys-Arg-Ile-Val-Gln-Arg-Ile-Lys-Asp-Phe-Leu-Arg-NH2 
   Table 10. Sequence of peptides synthesized. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Structure of KR-12 (above) and structure of analog (below) 
 
6.2. SYNTHESIS 
6.2.1. Synthesis strategy 
These peptides are synthesized manually by SPPS following the Fmoc/tBu protection 
strategy. To prevent the polymerization of the amino acid, the alpha amino group and the reactive 
chains are protected with a temporary protecting group. In this protection, the alpha nitrogen of 
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the amino acids is protected with the base labile Fmoc group while the side chains are protected 
with acid labile groups. This strategy is called orthogonal protection, which it means that the side 
chain protecting groups can be removed without affecting the N-terminal protection and vice 
versa. It is an advantage because Fmoc is removed in each coupling (in basic conditions); while 
the protecting group of the lateral chain remains unaffected until de cleavage (in acidic 
conditions). 
First, Fmoc-Val-OH is coupled to the resin BHA as a reference amino acid. This solid support 
is a benzhydrylamine linker bound to a polystyrene matrix, which need a pre-treated as explained 
in Section 5.3.1.1. This couple facilitates the SPPS because it could be used for amino acids 
analysis. The reaction is carried out with three equivalents of each reagent in DMF for 1 hour, 
shown in Section 5.3.1.4. 
Once the Fmoc is removed, the Rink Linker is coupled following the same steps as is 
explained in Section 5.3.1.3. Linkers are chemical entities to “link” the peptide sequence to the 
resin during SPPS. The Linker used is a benzhydrylamine functionalized with two methoxy groups 
at ortho and para positions. This coupling enables the cleavage of the RL-peptide bond with a 
solution of TFA in H2O and obtain the peptide with the C-terminal end in the carboxamide form. 
 
Figure 5. Reference AA and RL coupling to BHA resin. 
 
For the elongation of the peptide chain, the coupling of amino acid to the peptide resin is the 
crucial part of the SPPS method for a good rate and yield. Each amino acid coupling is carried 
out with 3 eq. of Fmoc-AA-OH, 3 eq. of DIC and 3 eq. of HOBt in DMF for 1h. The efficiency of 
the coupling needs to be controlled by ninhydrin test.  
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The peptide synthesis is based on the formation of an amide bond between a carboxylic acid 
and an amino group of and amino acid. First of all, it is necessary to activate the acid carboxylic, 
because if not, an acid-basic reaction will take place. In order to avoid this, DIC is used as an 
activate agent of the carboxylic acid of the amino acid by introducing a good leaving group on the 
carbonyl carbon. An O-acylisourea is formed and can react with the amine to yield the amide. 
 
 
 
 
 
 
Figure 6. Mechanism of carboxylic acid activation 
 
The first priority is to find the optimal combination of high coupling rate and minimal 
racemization. The product, O-acylisourea, increases the tendency to racemize. The mechanism 
involves the abstraction of the α-hydrogen from the α-carbon of the activated amino acid by direct 
formation of an enolic intermediate. Racemization also occurs by an alternative mechanism 
forming a 5-membered oxazolone ring. (Figure 7) [11] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Mechanism of base-catalysed racemization during activation. 
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In order to improve the efficiency of the SPPS technique by minimizing the racemization, a 
nucleophile such as HOBt is added. It forms active esters that will react with amino groups with 
little racemization, shown in Figure 8. 
 
Figure 8. Mechanism of HOBt coupling. 
 
Finally, the activated carboxylic acid can be attached by an unprotected amino group of a 
second amino acid via nucleophilic addition to form a tetrahedral intermediate, which is easily 
broken because the benzotriazolyl ester is a good leaving group, see in Figure 9. The urea by-
product and excess reagents are eliminated by vacuum filtration.  
 
Figure 9. Mechanism of chain elongation. 
 
 
Before the next amino acid coupling the Fmoc group must be removed. Fmoc is a basic labile 
protector group, thus it will be treated with 20% piperidine/DMF solution as it is explained in 
Section 5.3.1.4. The Fmoc group is removed when a base abstract the relatively acidic proton 
from the fluorenyl ring system, leading to a β-elimination and the formation of dibenzofulvene and 
carbon dioxide. The mechanism for deprotection is shown in Figure 10. 
 
Figure 10. Mechanism of Fmoc deprotection. 
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6.2.2. Purification and characterization  
The peptides synthesized are obtained with moderate yield because in SPPS there are many 
steps where it is easy to loss product. These steps could be ninhydrin test, mini-cleavage in order 
to verify the correctly elongation of the chain and also side reactions that leads to the not desired 
product. The results are obtained are shown in Table 11. 
 
Peptide η cleavage [%] η purification [%] η synthesis [%] Purity [%] 
KR-12 91 18 10,8 99 
Analog 94 20 12,3 >99 
Table 11. Synthesis yields and purity of the synthesized peptides. 
7. DETERMINATION OF MINIMUM INHIBITORY 
CONCENTRATION 
7.1. GRAM-NEGATIVE AND GRAM-POSITIVE 
The difference between Gram-negative and Gram-positive it is based on their cell wall 
composition. Gram-positive bacteria have cell walls composed of thick layers of peptidoglycan 
(20-30 nm) and Gram-negative have thin layer (8-12 nm).  
In the positive one, these bacteria have a single layered, are straight, less elastic and more 
rigid. While in the negative one, these bacteria have bilayer, are wavy, uneven, more elastic and 
less rigid. Moreover, they have outer membrane (external to the peptidoglycan cell wall) with 
lipopolysaccharide component not found in Gram-positive bacteria. 
In Gram stain test the Gram-positive retains crystal violet dye and stain blue/purple, 
meanwhile, Gram-negative can be decolorized and stain pink/red. 
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Figure 11. Difference between Gram-positive and Gram-negative cell wall. [14] 
 
7.2. BACTERIA 
A brief description of each bacteria: 
-Escherichia coli (ATCC 25922): is a Gram-negative and rod-shaped bacterium that can be 
found in the intestines of some animals. Most types of E. coli are harmless and can help digestion 
processes, food breakdown and absorption and vitamin K production. But some strains can cause 
bloody diarrhea, several anemia or kidney failure when someone gets infected by contaminated 
water or food. Nowadays, the resistance of this bacteria to antibiotics has increased. 
-Pseudomonas aeruginosa (ATCC 27853): is a Gram-negative and rod-shaped bacterium 
that can cause disease in plants and animals. It can cause urinary tract infections, respiratory 
system infections, gastrointestinal infections, blood infections and others. Usually it is found in 
soil, water and skin flora. It is a multidrug resistant pathogen and has a low susceptibility to 
antibiotics. 
-Acinetobacter baumannii (ATCC 19609): is a Gram-negative short, round and rod-shaped 
bacterium. They are often found in soil samples and occasionally it can be found in environmental 
soil and water samples. This bacterium has a high antibiotic resistance that is one of the 
responsible for nosocomial infections.  
-Staphylococcus aureus (ATCC 25293): is a Gram-positive and round-shaped bacterium that 
is usually found on the skin and hair as well as in the noses and throats of animals. This bacterium 
can cause many different typed of infections such as pneumonia, endocarditis, osteomyelitis. Like 
A. baumannii, is one on the main cause of nosocomial infections. 
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7.3. RESULTS AND DISCUSSION 
The results of the MIC test are determined visually using an amplifier to observe the turbity 
and then it is possible to determine bacteria growth.  
MIC is the lowest concentration of antibiotic which inhibit the visible growth of bacteria. Thus, 
the values in Table 12 are referred to the peptide concentration in the first well where the bacteria 
did not grow. 
Bacteria 
Peptide 
 MIC [µg/mL]   
E. coli P. aeruginosa A. baumannii S. aureus 
KR-12 32-64 64 >128 >128 
Analog 16 32 32 32 
Table 12.  MIC results. 
First of all, it is necessary to emphasize that there is no difference with the effectiveness 
against Gram-negative and Gram-positive bacteria. All the values are very high so both peptides 
are not very active against them. But when a fatty acid group is coupled (Analog) this substituent 
increases the hydrophobicity of the molecule, which improves the activity. 
It has been demonstrated that KR-12 is more active against E. coli, then with P. aeruginosa 
and finally with A. baumannii and S. aureus equally. Analog is also more active with E. coli and 
then with the others equally. 
So, the results of MIC test show that de KR-12 analog presents the best antimicrobial activity 
because with a lower concentration of it can inhibit the growth of bacteria. 
8. HEMOLYSIS ASSAY 
8.1. GENERAL ASPECTS  
Hemolysis is the rupture of red blood cells (erythrocytes) with release of hemoglobin into the 
plasma. Erythrocytes have a lifespan of 110-120 days. After dying they break down and are 
removed from the circulation. With diseases or medicaments this breakdown of red blood cells is 
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increased. This requires that the bone narrow must produce more erythrocytes than normal. They 
can break down due to defects in the cell, infections or immunity reactions for example. 
The hemolysis assay is strongly influenced by the tonicity of the medium in which red blood 
cells are placed. If erythrocytes are placed in a hypotonic solution such as distilled water, the 
water induces lyses of erythrocyte membrane because goes into red blood cells through an 
osmosis process. On the contrary, if it is used TBS (which is a buffer solution made by TRIS and 
NaCl), this solution avoids hemolysis caused from medium because it gives the isotonic salt 
concentration. Moreover, TBS is used to keep the physiological conditions (pH between 7,4 and 
8,0) of most living microorganisms. So, distilled water is used to obtain the 100% hemolysis 
control and TBS is used as 0% of hemolysis control. A toxicity evaluation is obtained from the 
percentage of lysis cells according to peptide concentration.  
8.2. RESULTS AND DISCUSSION 
The percentage of hemolysis is calculated using the following formula: 
 
 
Figure 12. Percentage of hemolysis equation (A: absorbance) 
The relationship between the percentage of hemolysis and the concentration of each peptide 
is shown in Figure 13. 
 
 
 
 
 
 
 
 
 
Figure 13. Plot of peptide concentration vs percentage of hemolysis. 
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For each peptide, the analysis was done twice. Such as some results of one KR-12 sequence 
were contaminated, after a few days the test was repeated. But the results were not coherent 
because it had passed 8 days since blood was extracted and it was not good. Thus, I have two 
replicates of Analog and just once of KR-12. 
To evaluate percent hemolysis, the release of hemoglobin into the surrounding medium is 
measured via absorbance on a microtiter plate. 
In the first place, with this assay has been demonstrated that when the concentration of 
peptide increases the % of hemolysis also gets bigger. 
The main results of this investigation are the considerable difference between both peptides. 
The analog which has been coupled a fatty acid is more hydrophobic and is also more hemolytic. 
A good antibacterial peptide should have low MIC values (more active) and low hemolytic 
activity (less toxic). KR-12 is less active but has a good hemolytic activity. Analog was created in 
order to improve KR-12 activity but as a consequence of this decrease in MIC values the peptide 
has become more toxic. 
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10. CONCLUSIONS 
The conclusions reached in this work are: 
• Solid phase peptide synthesis by Fmoc/tBu strategy is very effective and useful to 
obtain the desired peptides with high purities (≥99%).  
• It is possible to purify the obtained peptides by semi-preparative HPLC. However, 
the yields are moderate because this synthesis have multiple steps which causes 
product losses. Also, analytical HPLC and ESI mass spectroscopy are good 
techniques to characterize them. 
• The determination of minimum inhibitory concentration allows to know and compare 
the antimicrobial activity of the synthesized peptides. 
• The hemolysis assays allows to know and compare the toxicity of the synthesized 
peptides.  
• It has been possible to obtain a KR-12 analog more active. But as consequence of 
the hydrophobicity of the fatty acid group added the peptide is also more toxic. 
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12. ACRONYMS 
AA  Amino acid 
ACN  Acetonitrile 
AMP  Antimicrobial peptide 
ATCC American Type Culture Collection  
BHA  Benzhydrylamine resin 
Boc  tert-butyloxycarbonyl 
tBu  tert-butyl 
CFU  Colony-forming unit 
DCM  Dichloromethane 
DIEA  N,N’-Diisopropylethylamine 
DIC  N,N’-Diisopropylcarbodiimide 
DMF  N,N’-Dimethylformamide 
Eq.  Equivalents 
ESI  Electrospray ionization 
f  Functionality 
Fmoc Fluorenylmethyloxycarbonyl 
h  Hours 
HOBT 1-Hydroxybenzotriazole 
HPLC High Performance Liquid Chromatography 
m/z  Mass-to-charge ratio 
MHB  Muller Hinton-Broth 
MIC  Minimum inhibitory concentration 
min  Minutes 
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mL  Milliliter 
MS  Mass spectroscopy 
nm  Nanometres 
Pbf  2,2,4,6,7-Pentamethyldihydrobenzofuran-5-sulfonyl              
RL  Rink Linker 
RP-HPLC Reverse Phase High Performance Liquid Chromatography 
r.p.m.  Revolutions per minute 
SPPS Solid Phase Peptide Synthesis 
TBS   Tris-buffered saline 
TFA  Trifluoroacetic acid 
TIS  Triisopropylsilane 
TRIS  Tris(hydroxymethyl)aminomethane 
Trt  Triphenylmethyl (trityl) 
UFC  Colony-forming unit 
UV  Ultraviolet  
 
 
 
 
Synthesis and study of antibiotic peptides  37 
 
APPENDICES 
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APPENDIX 1: AMINO ACIDS AND PROTECTING 
GROUPS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   (L)-Arginina                (L)-Aspartic acid           (L)-Glutamine  
       L-Arg                        L-Asp                        L-Gln     
   (L)-Glycine            (L)-Isoleucine              (L)-Leucine           
        L-Gly      L-Ile                                       L-Leu 
  
        (L)-Lysine         (L)-Phenylalaniene  (L)-Valine 
           L-Lys                 L-Phe       L-Val 
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   Tert-butyloxycarbonyl                 Tert-butyl                    Fluorenylmethyloxycarbonyl 
            (Boc)                        (tBu)                        (Fmoc)      
   2,2,4,6,7-Pentamethyldihydrobenzofuran-5-sulfonyl             Tryphenylmethyl                 
                                   (Pbf)                                                              (Trt)                    
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APPENDIX 2. CHROMATOGRAMS OF PURE PEPTIDES 
 
 
 
 
Figure 14. HPLC chromatograms of KR-12 and analog with linear gradient from 10% to 25% and 30% to 
45% of B for 30 minutes respectively; UV detection at 220nm. 
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APPENDIX 3. ESI SPECTRA OF PURE PEPTIDES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. ESI spectra of pure peptides: KR-12 above and analog below. 
 
    
